Table 1.

Notice of compliance dates for osteoporosis medications and current public formulary listing status in British Columbia and Ontario [5, 11]

Drug	Strength	Regimen	Notice of compliancea	BC PharmaCare listing status	Ontario Drug Benefit Formulary listing status
Bisphosphonate
Etidronate and calcium	400/500 mg tab	14 days oral etidronate then 76 days oral calcium	19 Jul 1995	General benefits (since 1995)	General benefits (since 1996)
Alendronate	10 mg tab	Daily—oral	18 Dec 1995	Limited coverageb	General benefits (since January 2007)c
	70 mg tab	Weekly—oral	04 Feb 2002
Risedronate	5 mg tab	Daily—oral	17 Jul 2000	Limited coverageb	General benefits
	35 mg tab	Weekly—oral	09 Dec 2002		(since June 2007)c
	75 mg tab	Monthly—oral (2 consecutive days)	17 Jul 2007	Not listed	Not listed
	150 mg tab	Monthly—oral	24 Sep 2008	Not listed	General benefits (since July 2010)
Zoledronic acid	5 mg/100 ml	Annual infusion	29 Oct 2007	Not listed	Limited coveraged
Other
Calcitonin	200 U/spr	Daily—nasal spray	01 Sep 1999	Not listed	Limited coveragee
Denosumab	60 mg/ml	Semi-annual injection	06 Aug 2010	Not listed	Not listed
Raloxifene	60 mg tab	Daily—oral	06 Nov 1998	Limited coveragef	Limited coverageg
Teriparatide	250 μg/ml	Daily—subcutaneous injection	03 Jun 2004	Not listed	Not listed

General benefits covered without restriction, Limited coverage covered if specific clinical criteria have been met, Not listed not covered unless approved through Individual Clinical Review

^aNotice of compliance dates provided only for the first available dosing of each agent. We have not included oral bisphosphonate combination therapy

^bAvailable through special authority: clinical or radiographically documented fracture due to osteoporosis or patients who are receiving or expected to receive the equivalent of 7.5 mg/day of prednisone equivalent for 90 consecutive days or longer

^cLimited use history, Nov 2000 (alendronate) and Mar 2001 (risedronate): failed^g etidronate therapy or experience intractable side effects with etidronate or documented allergy which precludes continuation with etidronate therapy; Apr 2003 (alendronate/risedronate): above or two of the following three criteria: (1) bone mineral density T-score <−3.0, (2) aged 75 or more years, and (3) prior osteoporosis-related fracture

^dAvailable under the exceptional access program: treatment of osteoporosis in persons unable to absorb or take oral products

^eAvailable under the exceptional access program: treatment of osteoporosis in persons who have failed^g, experienced intractable side effects to or have contraindication to all of the available Formulary alternatives (oral bisphosphonate and if patient is female raloxifene)

^fAvailable through special authority: clinical or radiographically documented fracture due to osteoporosis or unsatisfactory clinical response, defined as a new fragility fracture after 1 year adherence to alendronate or risedronate

^gFailed: continued loss of bone mineral density of more than 3% after 2 years of therapy, new fracture after 1 year of therapy